Genovac Acquires the Carterra LSA® Instrument to Enable State-of-the-Art Antibody Screening and Characterization Services
Genovac becomes Carterra’s 100th LSA placement throughout the world
Fargo, North Dakota and Salt Lake City, Utah—April 20, 2022— Genovac, a leading contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research market segments, and Carterra, Inc., the world leader in label-free high-throughput antibody screening and characterization, today announced that Genovac has acquired Carterra’s LSA platform for use in its discovery services.
Genovac, previously a part of Aldevron before a management buyout in 2020, has been providing discovery services to life science researchers since 1999 from its site in Freiburg, Germany. More recently, Genovac added production, characterization, and cell line development capabilities to its site located in the North Dakota State University Research and Technology Park in Fargo, North Dakota.
“Since our launch of Genovac, we’ve been completely focused on serving our antibody discovery clients with the most robust and effective discovery and production capabilities, utilizing the most advanced technologies available,” said Brian Walters, Genovac’s CEO. “We’re thrilled to add Carterra’s LSA, the most advanced, high-throughput epitope binning and affinity measuring platform in the world, to our Fargo facility.”
Carterra launched the LSA antibody discovery and characterization platform in 2018 utilizing high throughput Surface Plasmon Resonance (HT-SPR) technology and has quickly made it the standard in 16 of the largest 20 pharmaceutical companies, biotechs, CROs, and government labs like the NIAID headed by Dr. Anthony Fauci. The applications across these customer types are equally broad and include identifying an antibody’s binding characteristics to its disease target and determining its mechanism of action through high-resolution epitope binning.
The speed at which antibodies can now be identified and characterized as potential drugs by Carterra’s LSA has improved on traditional methods by generating results 100 times faster while using 99% less sample. Sensitivity for finding the rarest of antibodies in a complex matrix is also now best-in-class.
Other highlights from Carterra’s stellar launch of the LSA include:
- The LSA was a primary tool used by Eli Lilly and AbCellera in the discovery of bamlanivimab, the world’s first COVID-19 therapeutic and fastest biologic ever to reach clinical trials. A Science paper: https://www.science.org/doi/full/10.1126/scitranslmed.abf1906
- The Gates-funded global COVID-19 Immunotherapy Consortium (CoVIC) used the LSA to help identify the most potent antibody drug candidates from all over the world. A Science Paper: https://www.science.org/doi/10.1126/science.abh2315
- In December of 2020, Carterra closed an equity round of financing from industry giant, PerkinElmer, who is also now the exclusive distributor of the LSA platform in the Asia-Pacific and Oceania regions.
“To have 100 instruments deployed across the globe in such a short time is striking, especially during the pandemic,” said Tim Germann, Chief Commercial Officer at Carterra. “We’re particularly pleased that Genovac has received the 100th LSA platform. Like Carterra, Genovac is completely committed to serving their clients with the most advanced technologies and services in biologics discovery.”